AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 18 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Two vaccines based on the Plasmodium falciparum merozoite surface protein 1 (MSP1) produced contrasting results in Aotus nancymai monkeys, report researchers at the U.S. National Institutes of Health.
A.W. Stowers and colleagues attempted to refine previously tested recombinant MSP1 vaccines and found that one approach was markedly more successful than the other. Their results were published in Infection and Immunity.
The researchers were able to obtain a highly pure and reproducible baculovirus product secreting the protein bvMSP1[42] for the first vaccine. When used in Aotus monkeys, six of seven were protected from subsequent P. falciparum infection, while one had to be treated for uncontrolled parasitemia.
The second vaccine, P30P2MSP1[19], had been used previously, but this time Stowers et al. refined it to optimize its expression. Nevertheless, it performed poorly, protecting only three of seven monkeys from parasitemia ("Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial," Infect Immun, March 2001;69(3):1536-1546). ...
Source: HighBeam Research, Two Vaccines Offer Varying Protection From P. falciparum In...